GSK Just Bet $11 Billion That It Can Win Lung Cancer
GSK is spending roughly $11 billion to acquire Nuvalent and its two FDA-reviewed lung cancer drugs, marking one of the biggest oncology deals of 2026. Wall Street likes the strategy but questions whether the price leaves any room for error.
Five years ago, GSK was the pharma giant that had basically walked away from cancer. The company had sold off oncology assets, doubled down on vaccines and HIV, and let rivals like AstraZeneca and Merck run the table in lung cancer. Now it's writing one of the biggest checks in oncology history to get back in the game.
GSK announced it will acquire Nuvalent, a precision oncology company focused on lung cancer, for $124 per share in cash. That values the deal at roughly $10.6 billion (or about $11 billion, depending on how you round). It's a 40% premium over Nuvalent's last closing price, and it ranks among the largest oncology acquisitions of 2026.
The message is loud and clear: GSK isn't just dabbling in cancer anymore. It's trying to buy its way back to the front of the line.
What GSK Is Actually Buying
Nuvalent isn't some early-stage biotech selling a dream on a whiteboard. The company has two drugs under FDA review right now, both targeting specific genetic mutations in non-small cell lung cancer (NSCLC), the most common type of lung cancer.
The first is zidesamtinib, which goes after a mutation called ROS1. Think of ROS1 as a broken switch inside cancer cells that tells them to keep growing. Zidesamtinib is designed to flip that switch off, and it can reach tumors that have spread to the brain. The FDA is expected to decide on its approval by September 18, 2026.
The second is neladalkib, which targets a different broken switch called ALK. Its FDA decision date is November 27, 2026. Zidesamtinib has earned a Breakthrough Therapy designation, which is the FDA's way of saying "we think this could be a meaningful advance."
In clinical trials, zidesamtinib showed a 44% response rate in patients whose cancer had already resisted other targeted treatments. Responses lasted a median of about 22 months. For neladalkib, the numbers are especially striking in a specific subgroup: patients with the ALK G1202R resistance mutation saw a . That's the kind of data that makes oncologists pay attention.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
68% response rate
Nuvalent also has a third drug, an early-stage HER2 inhibitor called NVL-330, plus preclinical programs. So GSK isn't buying one asset; it's buying a whole platform built around the same design philosophy: highly selective, brain-penetrating cancer drugs for genetically defined patient populations.
The Oncology Comeback Tour
To understand why GSK is spending this kind of money, you need to understand the hole the company dug for itself.
Under former CEO Andrew Witty, GSK pivoted away from cancer. While competitors were assembling world-class oncology portfolios, GSK was focused elsewhere. The result? By the mid-2020s, GSK had no major presence in lung cancer, no blockbuster checkpoint inhibitor to rival Merck's Keytruda, and a thin pipeline of late-stage cancer drugs compared to its peers.
The company has been trying to rebuild. It re-launched Blenrep (a multiple myeloma drug that had been pulled from the market). It started licensing antibody-drug conjugates. It acquired IDRx for about $1.15 billion earlier this year to get a targeted therapy for gastrointestinal stromal tumors. But those were singles and doubles.
Nuvalent is GSK swinging for the fences.
The company also has a ticking clock. Its blockbuster HIV drug dolutegravir starts losing patent protection in early 2028. GSK needs new revenue engines, and oncology is where the growth is. Management says the Nuvalent deal should start adding to sales and core operating profit by 2027 and support its ambitious target of £40 billion in annual sales by 2031.
Wall Street's Verdict: Smart Move, Steep Price
Analysts mostly agree the strategy makes sense. Where they disagree is whether GSK overpaid.
GSK shares dropped roughly 2.5-3.5% in London on the announcement. Meanwhile, Nuvalent's stock jumped nearly 40% to the offer price. That tells you something about who the market thinks got the better end of the deal.
Stifel analyst Laura Prendergast said the deal is "optimal for realizing the full potential" of Nuvalent's drugs, thanks to GSK's global commercial footprint. But she noted the timing surprised investors, who expected any buyer to wait until after launch and see more data before paying this much.
Barclays called the acquisition "conceptually sound" and "strategically logical" because it gives GSK de-risked assets and an entry point into lung cancer. The catch? Barclays analysts don't see either drug reaching "mega-blockbuster" status, which means the upside may be capped relative to the price tag.
Bloomberg Intelligence's Javier Manso Polo put it bluntly: at $10.6 billion, the deal "leaves little margin for error." Nuvalent's drugs will compete against entrenched players like Pfizer's Lorbrena in ALK-positive lung cancer. Lorbrena recently posted impressive long-term survival data, and that competition is partly why Nuvalent's stock had dipped before the deal was announced.
One institutional investor at Verso Investment Management called Nuvalent a "significant brick" in GSK's oncology rebuild. But Ketan Patel of Whitefriars family office argued that GSK is still playing catch-up and needs more deals to truly compete with Roche and Merck.
The Bigger Picture: Everyone Wants Precision Oncology
GSK isn't shopping alone. The biotech M&A market in 2025 and 2026 has been an absolute feeding frenzy for precision oncology assets.
Sanofi grabbed Blueprint Medicines for about $9.5 billion to get mutation-selective inhibitors. Genmab acquired Merus for roughly $8 billion to lock up bispecific antibody technology. Merck bought Terns Pharmaceuticals for $6.7 billion to bolster its blood cancer pipeline. These aren't random bets; they're all part of the same thesis. Big pharma believes the future of cancer treatment is defined by genetics, not tumor location.
The pattern is clear. If you're a biotech with a highly selective drug that targets a specific cancer mutation, penetrates the brain, and has clean clinical data, you're getting acquired. The question is how much you'll cost.
Can GSK Actually Pull This Off?
GSK plans to fund the deal through cash and debt, with no expected impact on its credit rating or dividend. The tender offer should launch within 10 business days, and the company is targeting a Q3 2026 close, pending regulatory clearance.
The financial mechanics aren't the hard part. The hard part is what comes next.
GSK needs to launch two cancer drugs in a competitive market where oncologists already have options they're comfortable prescribing. It needs to prove that zidesamtinib and neladalkib are better (or at least meaningfully different) enough to win market share. And it needs to expand both drugs into earlier lines of treatment, where the patient populations are larger but the competition is fiercer. Nuvalent already has a Phase 3 trial called ALKAZAR underway, testing neladalkib as a first-line treatment.
The $11 billion question isn't whether these are good drugs. The data suggests they are. The question is whether GSK, a company that abandoned oncology once before, can execute well enough to make this bet pay off.
History is watching. So is every analyst on Wall Street.
5 min read
Lilly's $25 Billion Shopping Spree Just Found a Painkiller That Skips the Opioid Problem
Eli Lilly quietly scooped up 4E Therapeutics, a startup with a first-in-class painkiller that skips opioid receptors entirely. It's the latest move in a $20 billion+ acquisition spree, and it could reshape how we treat chronic pain.
